Evidence map›Paper›PMID 21744132›Full record

ArticleCurrent rheumatology reports2011

Mucosal inflammation in spondylarthritides: past, present, and future.

Liesbet Van Praet, Filip Van den Bosch, Herman Mielants, Dirk Elewaut

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Current rheumatology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03058900 (Efficacy and Safety of Fecal Microbiota Transplantation), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03058900 nacompletednot on this mapstarted 2017, after this paper: background citation

Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Peripheral Psoriatic Arthritis: a 6-month, Double-Blind, Randomized, Placebo-Controlled Trial

TypeinterventionalSponsorOdense University HospitalRan2017 to 2020Enrolled31ConditionsPsoriatic ArthritisArmsFecal microbiota transplantation (FMT), Drug: Placebo (saline), Methotrexate (MTX)
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting tumor necrosis factor receptors in ankylosing spondylitis.Annals of the New York Academy of Sciences · 2019
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. The microbiome and psoriatic arthritis.Current rheumatology reports · 2014
    Review
  12. Polymorphism of HLA-B27: 105 subtypes currently known.Current rheumatology reports · 2013
    Review
  13. Enteropathic spondyloarthritis: from diagnosis to treatment.Clinical & developmental immunology · 2013
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Liesbet Van PraetDepartment of Rheumatology, Ghent University Hospital, De Pintelaan 185, 0K12-IB, 9000 Ghent, Belgium. liesbet.vanpraet@ugent.be
Filip Van den Bosch
Herman Mielants
Dirk Elewaut
Ghent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spondylarthritides (SpA) and inflammatory bowel disease (IBD) are idiopathic, chronic inflammatory disorders. Although they are very distinct and well-defined entities, there is clinical and genetic evidence supporting some degree of overlap between the pathogenesis of the two. Subclinical gut inflammation is present in up to two thirds of all SpA patients and can evolve into IBD. This subclinical gut inflammation has been shown to be strongly associated with joint inflammation, providing a clue for a common pathophysiologic background. Despite extensive research progress in the field over the past few years, many questions remain unanswered. In this paper, we focus on the clinical, genetic, and pathophysiologic overlap of SpA and IBD. Furthermore, we discuss some of the targets that may influence therapeutic decision making.

Indexed as

Antibodies, MonoclonalAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsBiomarkersCytokinesHumansInflammationInflammatory Bowel DiseasesIntestinal MucosaSpondylarthritisTumor Necrosis Factor-alphaAntibodies, MonoclonalAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsBiomarkersCytokinesTumor Necrosis Factor-alpha

Identifiers

PMID21744132
OpenAlexW1984522611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.